CNS Pharmaceuticals (NASDAQ:CNSP) Stock Price Up 0.4% – What’s Next?

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) shares rose 0.4% during trading on Wednesday . The stock traded as high as $4.71 and last traded at $4.61. Approximately 30,763 shares were traded during mid-day trading, a decline of 63% from the average daily volume of 82,085 shares. The stock had previously closed at $4.59.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of CNS Pharmaceuticals in a report on Monday, April 20th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $20.00.

CNS Pharmaceuticals Stock Up 3.6%

The company’s fifty day moving average price is $4.09 and its 200-day moving average price is $4.65. The stock has a market capitalization of $7.14 million, a PE ratio of -0.17 and a beta of 3.06.

CNS Pharmaceuticals (NASDAQ:CNSP) last released its earnings results on Thursday, May 14th. The company reported ($7.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($8.82) by $1.52.

Insider Activity

In other CNS Pharmaceuticals news, Director Faith L. Charles bought 7,100 shares of the stock in a transaction dated Monday, May 18th. The stock was purchased at an average cost of $4.79 per share, for a total transaction of $34,009.00. Following the completion of the acquisition, the director owned 7,100 shares of the company’s stock, valued at approximately $34,009. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 0.01% of the company’s stock.

Institutional Investors Weigh In On CNS Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in CNSP. Armistice Capital LLC bought a new stake in CNS Pharmaceuticals in the 2nd quarter worth approximately $335,000. Boothbay Fund Management LLC bought a new stake in CNS Pharmaceuticals in the 4th quarter worth approximately $71,000. Finally, Ikarian Capital LLC bought a new stake in CNS Pharmaceuticals in the 4th quarter worth approximately $241,000. Institutional investors own 14.02% of the company’s stock.

CNS Pharmaceuticals Company Profile

CNS Pharmaceuticals, Inc, headquartered in Houston, Texas, is a clinical-stage biopharmaceutical company focused on developing therapies for aggressive central nervous system tumors. The company’s lead candidate, berubicin, is an anthracycline derivative engineered to cross the blood-brain barrier for the treatment of glioblastoma multiforme and other brain cancers. In addition to berubicin, CNS Pharmaceuticals is advancing WP1066, an immunotherapy agent designed to inhibit the STAT3 signaling pathway and enhance anti-tumor immune activity in the tumor microenvironment.

Berubicin has completed a Phase 1 clinical trial in patients with recurrent glioblastoma, where it demonstrated proof-of-concept signals, and is currently in Phase 2 development.